CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Sell
37
SSY Quote, Financials, Valuation and Earnings
Last price:
$0.92
Seasonality move
:
7.18%
Day range:
$0.86 - $0.95
52-week range:
$0.53 - $1.91
Dividend yield:
0%
P/E ratio:
6.39x
P/S ratio:
0.20x
P/B ratio:
0.45x
Volume:
7.6K
Avg. volume:
15.2K
1-year change:
42.08%
Market cap:
$6.3M
Revenue:
$32.4M
EPS (TTM):
$0.14
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, SunLink Health Systems has -- downside to fair value with a price target of -- per share.
SSY vs. S&P 500
-
Over the past 5 trading days, SunLink Health Systems has underperformed the S&P 500 by -7.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
SunLink Health Systems does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
SunLink Health Systems revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter SunLink Health Systems reported revenues of $7.9M.
Earnings Growth
-
SunLink Health Systems earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter SunLink Health Systems reported earnings per share of -$0.19.
Enterprise value:
-1.7M
EV / Invested capital:
--
Price / LTM sales:
0.20x
EV / EBIT:
--
EV / Revenue:
-0.06x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.38x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$12.1M
Return On Assets:
5.37%
Net Income Margin (TTM):
3.2%
Return On Equity:
7.13%
Return On Invested Capital:
7.13%
Operating Margin:
-12.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $38.5M | $33.3M | $31.2M | $8.5M | $7.9M | |
| Gross Profit | $18.2M | $12.7M | $12.1M | $3.4M | $3M | |
| Operating Income | -$1.6M | -$2.5M | -$3.7M | -$433K | -$1M | |
| EBITDA | -$221K | -$1.1M | -$2.3M | -$115K | -$688K | |
| Diluted EPS | -$0.42 | -$0.95 | $0.14 | -$0.44 | -$0.19 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $19.5M | $20.1M | $15M | $13.7M | $14.2M | |
| Total Assets | $28.5M | $30.2M | $26.2M | $18.8M | $17.9M | |
| Current Liabilities | $9.1M | $6.9M | $5.6M | $5.2M | $3.5M | |
| Total Liabilities | $12M | $8M | $6.6M | $5.8M | $3.8M | |
| Total Equity | $16.5M | $22.2M | $19.6M | $13M | $14.1M | |
| Total Debt | $3.2M | -- | $30K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$604K | -$1.3M | -$3.5M | -$393K | -$1.2M | |
| Cash From Investing | -$2.6M | -$1.7M | $9.5M | -$369K | $1.7M | |
| Cash From Financing | $55K | -$24K | -- | -$3K | -- | |
| Free Cash Flow | -$3.1M | -$2.7M | -$4.5M | -$741K | -$1.3M | |
SSY
Sector
Market Cap
$6.3M
$34.5M
Price % of 52-Week High
46.86%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.79%
1-Year Price Total Return
42.08%
-42.08%
Beta (5-Year)
1.203
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.93
200-day SMA
Buy
Level
$0.87
Bollinger Bands (100)
Sell
Level
0.82 - 1.02
Chaikin Money Flow
Sell
Level
-109.8M
20-day SMA
Sell
Level
$0.91
Relative Strength Index (RSI14)
Sell
Level
46.98
ADX Line
Buy
Level
14.49
Williams %R
Neutral
Level
-79.2644
50-day SMA
Sell
Level
$0.96
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
353.7M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.6834)
Buy
CA Score
(Annual)
Level (0.8187)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (0.2131)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
SunLink Health Systems Inc is engaged in providing retail pharmacy services. The company operates its business through segments namely the Healthcare Services segment and Pharmacy segment. The Healthcare Services segment includes subsidiaries that own and operate licensed-bed, acute care hospitals, which includes bed geriatric psychology unit, and nursing home; own medical buildings, which are leased to unaffiliated healthcare providers, and adjacent vacant land; and provides information technology to outside customers. The Pharmacy segment, which is the key revenue generator is composed of retail pharmacy products and services that are conducted in rural markets; institutional pharmacy services; pharmacy services; and durable medical equipment.
Stock Forecast FAQ
In the current month, SSY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SSY average analyst price target in the past 3 months is --.
-
Where Will SunLink Health Systems Stock Be In 1 Year?
According to analysts, the consensus estimate is that SunLink Health Systems share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About SunLink Health Systems?
Analysts are divided on their view about SunLink Health Systems share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that SunLink Health Systems is a Sell and believe this share price will rise from its current level to --.
-
What Is SunLink Health Systems's Price Target?
The price target for SunLink Health Systems over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SSY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for SunLink Health Systems is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SSY?
You can purchase shares of SunLink Health Systems via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase SunLink Health Systems shares.
-
What Is The SunLink Health Systems Share Price Today?
SunLink Health Systems was last trading at $0.92 per share. This represents the most recent stock quote for SunLink Health Systems. Yesterday, SunLink Health Systems closed at $0.90 per share.
-
How To Buy SunLink Health Systems Stock Online?
In order to purchase SunLink Health Systems stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 22.52% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is down 0% over the past day.
Buy
53
SRPT alert for May 7
Sarepta Therapeutics [SRPT] is down 21.54% over the past day.
